Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

This study is testing a gene therapy called TN-401 for a rare inherited heart condition called ARVC (arrhythmogenic right ventricular cardiomyopathy) caused by a mutation in the PKP2 gene. This condition causes dangerous heart rhythm problems. **You may be eligible if...** - You have a confirmed PKP2 gene mutation (pathogenic or likely pathogenic) - You have been diagnosed with ARVC based on standard diagnostic criteria - You have a functioning implantable defibrillator (ICD) already in place for at least 9 months - You have frequent irregular heartbeats (premature ventricular contractions) - Your heart pumping function is reasonably preserved (ejection fraction ≥50%) - Your heart failure symptoms are mild to moderate (NYHA Class I-III) **You may NOT be eligible if...** - You have had a procedure to ablate (burn) heart tissue within 6 months or plan to have one - You have had a prior heart attack - You have severe right heart failure or Class IV heart failure - You have significant kidney or liver disease Talk to your doctor to see if this trial is right for you.